1
|
Xie JM, Leng Y, Cui XY, Min CG, Ren AM, Liu G, Yin Q. Theoretical Study on the Formation and Decomposition Mechanisms of Coelenterazine Dioxetanone. J Phys Chem A 2023; 127:3804-3813. [PMID: 37083412 DOI: 10.1021/acs.jpca.3c00453] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/22/2023]
Abstract
Bioluminescence has been drawing broad attention due to its high signal-to-noise ratio and high bioluminescence quantum yields, which has been widely applied in the fields of biomedicine, bioanalysis, and so on. Among numerous bioluminescent substrates, coelenterazine is famous for its wide distribution. However, the oxygenation reaction mechanism of coelenterazine is far from being completely understood. In this paper, the formation and decomposition mechanisms of coelenterazine dioxetanone were investigated via density functional theory (DFT) and time-dependent (TD) DFT approaches. The results showed that the oxygenation reaction first occurred along the triplet-state potential energy surface (PES), after the intersystem crossing (ISC), second jumped to the diradical-state PES, and ultimately formed coelenterazine dioxetanone. For the decomposition mechanism of dioxetanone, the computational results showed that the chemiexcitation of neutral dioxetanone was more efficient than that of other dioxetanone species. Moreover, the diradical properties and the degree of ionic character are modified by the counter ions.
Collapse
Affiliation(s)
- Jin-Mei Xie
- School of Materials Science and Engineering, Kunming University of Science and Technology, Kunming 650093, P. R. China
| | - Yan Leng
- Research Center for Analysis and Measurement, Kunming University of Science and Technology, Kunming 650093 P. R. China
| | - Xiao-Ying Cui
- Research Center for Analysis and Measurement, Kunming University of Science and Technology, Kunming 650093 P. R. China
| | - Chun-Gang Min
- Research Center for Analysis and Measurement, Kunming University of Science and Technology, Kunming 650093 P. R. China
| | - Ai-Min Ren
- Institute of Theoretical Chemistry, College of Chemistry, Jilin University, Changchun 130023, P. R. China
| | - Gang Liu
- Institute of Chemical and Industrial Bioengineering, Jilin Engineering Normal University, Changchun 130052, P. R. China
| | - Qinhong Yin
- Faculty of Narcotics Control, Yunnan Police College, Kunming 650223, P. R. China
| |
Collapse
|
2
|
Sukhbaatar A, Kodama T. Protocols for the Evaluation of a Lymphatic Drug Delivery System Combined with Bioluminescence to Treat Metastatic Lymph Nodes. Methods Mol Biol 2022; 2524:333-346. [PMID: 35821485 DOI: 10.1007/978-1-0716-2453-1_27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Bioluminescence (BL) imaging is a powerful non-invasive imaging modality widely used in a broad range of biological disciplines for many types of measurements. The applications of BL imaging in biomedicine are diverse, including tracking bacterial progression, research on gene expression patterns, monitoring tumor cell growth/regression or treatment responses, determining the location and proliferation of stem cells, and so on. It is particularly valuable when studying tissues at depths of 1 to 2 cm in mouse models during preclinical research. Here we describe the protocols for the therapeutic evaluation of a lymphatic drug delivery system (LDDS) using an in vivo BL imaging system (IVIS) for the treatment of metastatic lymph nodes (LNs) with 5-fluorouracil (5-FU). The LDDS is a method that directly injects anticancer drugs into sentinel LNs (SLNs) and delivers them to their downstream LNs. In the protocol, we show that metastases in the proper axillary LN (PALN) are induced by the injection of luciferase-expressing tumor cells into the subiliac LN (SiLN) of MXH10/Mo-lpr/lpr (MXH10/Mo/lpr) mice. 5-FU is injected using the LDDS into the accessory axillary LN (AALN) to treat tumor cells in the PALN after the tumor cell growth is confirmed in the PALN. The tumor growth and therapeutic effects are evaluated by IVIS. This method can be used to evaluate tumor growth and efficacy of anticancer drugs/particles, radiotherapy, surgery, and/or a combination of these methods in various experimental procedures in the oncology field.
Collapse
Affiliation(s)
- Ariunbuyan Sukhbaatar
- Laboratory of Biomedical Engineering for Cancer, Graduate School of Biomedical Engineering, Tohoku University, Sendai, Miyagi, Japan
| | - Tetsuya Kodama
- Laboratory of Biomedical Engineering for Cancer, Graduate School of Biomedical Engineering, Tohoku University, Sendai, Miyagi, Japan.
- Department of Electronic Engineering, Graduate School of Engineering, Tohoku University, Sendai, Miyagi, Japan.
| |
Collapse
|
3
|
Maynard J, Hart P. The Opportunities and Use of Imaging to Measure Target Engagement. SLAS DISCOVERY 2019; 25:127-136. [PMID: 31885303 DOI: 10.1177/2472555219897270] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Lack of efficacy and poor safety outcomes are deemed to be the greatest causes of clinical failure of novel therapeutics. The use of biomarkers that give accurate information on target engagement, providing confidence that pharmacological activity in the target organ is being achieved, is key in optimizing clinical success. Without a measurement of target engagement, it can be very difficult to discern the basis for any lack of efficacy of a drug molecule within the pharmaceutical industry. Target engagement can be measured in both an in vitro and in vivo setting, and in recent years imaging measurements have been used frequently in drug discovery and development to assess target engagement and receptor occupancy in both human and animal models. From this perspective, we assess and look at the advancements in both in vivo and ex vivo imaging to demonstrate the enormous potential that imaging has as an application to provide a greater understanding of target engagement with a correlative therapeutic impact.
Collapse
Affiliation(s)
| | - Philippa Hart
- Medicines Discovery Catapult, Alderley Park, Cheshire, UK
| |
Collapse
|
4
|
Cao J, Hu Y, Shazeeb MS, Pedraza CE, Pande N, Weinstock D, Polites GH, Zhang W, Chandross KJ, Ying X. In Vivo Optical Imaging of Myelination Events in a Myelin Basic Protein Promoter-Driven Luciferase Transgenic Mouse Model. ASN Neuro 2019; 10:1759091418777329. [PMID: 29806482 PMCID: PMC5987236 DOI: 10.1177/1759091418777329] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
The compact myelin sheath is important for axonal function, and its loss
can lead to neuronal cell death and irreversible functional deficits.
Myelin is vulnerable to a variety of metabolic, toxic, and autoimmune
insults. In diseases like multiple sclerosis, there is currently no
therapy to stop myelin loss, underscoring the need for neuroprotective
and remyelinating therapies. Noninvasive, robust techniques are also
needed to confirm the effect of such therapies in animal models. This
article describes the generation, characterization, and potential uses
for a myelin basic protein-luciferase (MBP-luci) transgenic mouse
model, in which the firefly luciferase reporter gene is selectively
controlled by the MBP promoter. In vivo
bioluminescence imaging can be used to visualize and quantify
demyelination and remyelination at the transcriptional level,
noninvasively, and in real time. Transgenic mice were assessed in the
cuprizone-induced model of demyelination, and luciferase activity
highly correlated with demyelination and remyelination events as
confirmed by both magnetic resonance imaging and postmortem
histological analysis. Furthermore, MBP-luci mice demonstrated
enhanced luciferase signal and remyelination in the cuprizone model
after treatment with a peroxisome proliferator activated
receptor-delta selective agonist and quetiapine. Imaging sensitivity
was further enhanced by using CycLuc 1, a luciferase substrate, which
has greater blood–brain barrier penetration. We demonstrated the
utility of MBP-luci model in tracking myelin changes in real time and
supporting target and therapeutic validation efforts.
Collapse
Affiliation(s)
- James Cao
- 1 Translational In Vivo Model, Global Research Platform, Sanofi R&D, Framingham, MA, USA
| | - Yanping Hu
- 2 Multiple Sclerosis Cluster, Neuroscience Research, Sanofi R&D, Framingham, MA, USA
| | | | - Carlos E Pedraza
- 2 Multiple Sclerosis Cluster, Neuroscience Research, Sanofi R&D, Framingham, MA, USA
| | - Nilesh Pande
- 2 Multiple Sclerosis Cluster, Neuroscience Research, Sanofi R&D, Framingham, MA, USA
| | | | | | - Wenfei Zhang
- 5 Biostatistics and Programming, Sanofi R&D, Framingham, MA, USA
| | | | - Xiaoyou Ying
- 1 Translational In Vivo Model, Global Research Platform, Sanofi R&D, Framingham, MA, USA
| |
Collapse
|